Search Medical Condition
Please enter condition
Please choose location from dropdown

Nishikyo-Ku Kyoto-Shi, Japan Clinical Trials

A listing of Nishikyo-Ku Kyoto-Shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (143) clinical trials

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history) associated with the safety and effectiveness of evolocumab therapy for the patients with ...

Phase N/A

1.89 miles

Learn More »

The primary objective of this study is to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Phase

2.5 miles

Learn More »

Efficacy of Microcurrent Therapy for Treatment of Knee Pain

The purpose of this study is to evaluate the effect of microcurrent therapy at the knee pain.

Phase N/A

2.53 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.

Phase

2.61 miles

Learn More »

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

Phase

2.94 miles

Learn More »

A Double-masked Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

MEDI-551 is a genetically engineered humanized monoclonal antibody that binds to the B cell specific surface antigen CD19 resulting in the depletion of B cells. CD19 positive (CD19+) B-lineage plasmablasts are responsible for the production of autoantibodies against the AQP4 channel protein. The main objective of this study is to ...

Phase

2.94 miles

Learn More »

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

The objectives of this study are: to evaluate the safety, tolerability, and systemic pharmacokinetics (PK) of different doses of inhaled ALX-0171 in Japanese infants and young children hospitalized for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI). to evaluate the antiviral effect, clinical activity, immunogenicity, and pharmacodynamics (PD) of ...

Phase

3.06 miles

Learn More »

A Study to Assess Efficacy Safety Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).

The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Phase

3.09 miles

Learn More »

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Phase

3.09 miles

Learn More »

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

Phase

3.09 miles

Learn More »